All News
Global Alzheimer’s Platform Foundation Statement on FDA Accelerated Approval of Lecanemab
“With this approval, it is incumbent on Center for Medicare and Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure and the drug’s sponsors to offer this life-changing therapy to patients quickly, while prioritizing access and economic fairness.” Statement attributed to Global Alzheimer’s Platform Foundation President John Dwyer: Washington, D.C. (Jan. 6, 2023) — We applaud the Food […]
Battling The Silent Alzheimer’s EPIDEMIC in The Black Community with Roland Martin
GAP Associate Director of Recruitment & Strategic Initiatives, Dr. Tamiko MaGee Rodgers, was featured on the Roland Martin Unfiltered Daily Digital Show and spoke about Alzheimer’s disease clinical trials.
Global Alzheimer’s Platform Foundation (GAP) Hopeful With ARPA-H Appropriations
Washington, DC — December 23, 2022–Appropriations bills are not simply about funding. They are about people. That is why we are grateful that Congress prioritized funding for accelerated and disruptive Alzheimer’s disease research in the 2023 Omnibus Appropriations Bill. Increases in funding for the Advanced Research Projects Agency for Health (ARPA-H) and the National Institutes […]
ICER Fails People with Alzheimer’s Disease, The Global Alzheimer’s Platform Foundation Calls On Allies to Debunk Report
Washington, DC — December 23, 2022–The Institute for Clinical and Economic Review (ICER) has again failed in its attempt to value the benefit provided by a new, life-improving Alzheimer’s treatment, threatening millions of Americans who are living with Alzheimer’s disease. The report, “Beta-Amyloid Antibodies for Early Alzheimer’s Disease,” released yesterday, advances an analytical framework that […]
GAP President John Dwyer, on Lecanemab detailed results: “There is every reason for the Alzheimer’s community to have optimism today”
Washington, D.C. (Nov. 30, 2022) – “Following the positive, detailed results from Eisai on lecanemab, a monoclonal antibody therapy for the treatment of Alzheimer’s, there is every reason for the Alzheimer’s community to have optimism today. Thanks to the unwavering commitment of Eisai, its clinical trial partners, and most importantly, the people who participated in […]
Medicare Alzheimer’s Coverage Policy Advancing Clinical Trial Diversity Efforts
GAP President John Dwyer spoke with Cathy Kelly of Pink Sheet about the Bio-Hermes study, the necessity for diversity in #Alzheimers clinical trials, and how industry-sponsored trials are out pacing government-sponsored trials. Although Alzheimer’s stakeholders are dismayed by the treatment access restrictions imposed by the Medicare national coverage determination last spring, the policy has also jumpstarted […]
An Alzheimer’s Dx Comparison Study Wraps Up, Researchers Plan to Add Genomic Proteomic Profiling
GAP President, John Dwyer, spoke to Genome Web about the closing of our Bio-Hermes study, and what the results may do for the future of Alzheimer’s research. The Global Alzheimer’s Platform (GAP) has completed a first-of-its-kind cross sectional study comparing the performance of Alzheimer’s diagnostic assays. Topline results are expected in July of next year, […]
Left Out for too Long: New Alzheimer’s Research Focuses on Latinos
GAP-Net site, El Faro Health & Therapetuics was featured in AARP on the work they are doing to bring Alzheimer’s research to the Latino and Starr County communities. On a gloomy mid-November morning in 2021, Jessica Cantú stood in the parking lot outside a health center in the rural border community of Starr County, Texas, […]
First of its Kind Head-to-Head Study Comparing Leading Biomarkers for Detecting Alzheimer’s Disease Closes With Unprecedented Representation from Underrepresented Populations
The Global Alzheimer’s Platform Foundation (GAP) closed its ground-breaking blood-based and digital biomarker platform study, Bio-Hermes, which is powered to measure more than 36 technologies’ effectiveness across three stages of Alzheimer’s disease, while drawing from all races and ethnic groups affected by the disease. WASHINGTON, DC (Nov. 15, 2022) — In 18 months, the Global […]
Statement on Roche Announcement on Gantenerumab Attributed to John Dwyer, GAP Foundation President
The Global Alzheimer’s Platform Foundation (GAP) is grateful for Roche’s efforts and leadership on the gantenerumab study to treat Alzheimer’s disease. We applaud Roche’s robust and well-designed study, and for holding to an ongoing commitment to research in this field. Every clinical study improves our understanding of Alzheimer’s disease, so this data will be of […]